BIO-key International
BKYI
11 hedge funds and large institutions have $176K invested in BIO-key International in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
57% more funds holding
Funds holding: 7 → 11 (+4)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
70% less capital invested
Capital invested by funds: $594K → $176K (-$418K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$23.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.18K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$178K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$218 |
BKYI Hedge Fund Activity: Q4 2022 in Review
11 institutional investors reported a position in BIO-key International (BKYI) for Q4 2022, worth a combined $176K — down 70% from $594K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BKYI positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $23.1K. The largest seller was Vanguard Group, cutting an estimated $178K.
- 11 institutional investors held BIO-key International (BKYI) as of Q4 2022, up from 7 in Q3 2022.
- Funds reported $176K of BIO-key International stock for Q4 2022, down 70% quarter-over-quarter.
- 4 funds opened new BIO-key International positions in Q4 2022 and 0 closed out, a net change of +4 holders.
- The largest BIO-key International buyer in Q4 2022 was HRT Financial, an estimated $23.1K added.
- The largest BIO-key International seller in Q4 2022 was Vanguard Group, an estimated $178K sold.
Based on aggregated 13F filings for Q4 2022.